The Karnataka government has highlighted a huge gap between the landing cost of high‑value medicines and their MRP. The state has written to the Union Health Minister, urging the NPPA and the centre to act.
Key Developments
- Letter dated 23 September 2026 from Health Minister U.T. Khader seeks central action on price anomalies.
- FSDA inspections uncovered 253 drugs with mark‑ups ranging from 10‑times to over 52‑times the procurement cost.
- State demands: display of both landing cost and MRP on bills, expansion of the DPCO, and regulation of trade margins.
- Request for an inter‑ministerial expert group, a national data study, and amendment of the DPCO or its supplement.
Important Facts
Some highlighted price differentials are:
- Gufipol (Criticare): landing cost ₹86 → MRP ₹4,528 (≈52.6 times).
- Guficycline‑50 injection (GUFI): landing cost ₹160 → MRP ₹7,110 (≈44.4 times).
- Cytax 100 mg (cancer drug): landing cost ₹342 → MRP ₹3,836 (≈11.2 times).
- Adult Nebuliser Mask: landing cost ₹44.50 → MRP ₹950 (≈21.3 times).
- Other consumables such as IV sets, cannulas and masks show 16‑to‑20 times mark‑ups.
The FSDA’s special verification drive on 25‑26 September 2026 inspected 768 consumable items and 189 high‑cost drugs across Bengaluru and district headquarters. Preliminary findings confirm substantial price gaps, and the exercise will continue, focusing next on antiretroviral drugs, newer antibiotics, and critical medical devices.
Exam Relevance
These developments touch upon several UPSC syllabus areas:
- Health Governance – Role of state vs. centre, inter‑ministerial coordination, and the functioning of agencies like FSDA.
- Price Regulation – Understanding the DPCO, its scope, and the need to expand the NLEM.
- Public Finance & Consumer Protection – Impact of inflated drug prices on out‑of‑pocket expenditure and health equity.
- Policy Implementation – Mechanisms for transparency, audit, and enforcement in the pharmaceutical sector.
Way Forward
The state proposes a multi‑pronged approach:
- Mandate hospitals to print both landing cost and MRP on patient bills for full transparency.
- Expand the list of medicines under the DPCO and revise the NLEM to include more high‑value drugs.
- Set up an inter‑ministerial expert group to study national price data and recommend margin caps.
- Create a robust audit and enforcement mechanism, possibly through the NPPA, to curb profiteering.
Implementation will require coordination between state health departments, the centre, and regulatory bodies, ensuring that essential medicines remain affordable for the public.